Involvement of PPARα and PPARγ in apoptosis and proliferation of human hepatocarcinoma HepG2 cells

Cell Biochemistry and Function

Volumn 28, Issue 7, 2010, Pages 571-577

  Maggiora, Marina ^a   Oraldi, Manuela ^a   Muzio, Giuliana ^a   Canuto, Rosa Angela ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Apoptosis; Clofibrate; HepG2 cells; PGJ2; PPAR ; PPAR

Indexed keywords

CLOFIBRATE; FATTY ACID; FIBRIC ACID DERIVATIVE; ICOSANOID; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROSTAGLANDIN J2; PROTEIN BAD;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CLOFIBRATE; HEP G2 CELLS; HUMANS; LIGANDS; LIVER NEOPLASMS; OSMOLAR CONCENTRATION; PPAR ALPHA; PPAR GAMMA; PROSTAGLANDIN D2; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 78650458633     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1691     Document Type: Article

References (38)

1. Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-366.
2. Bardot O, Clemencet MC, Passilly P, Latruffe N. The analysis of modified peroxisome proliferator responsive elements of the peroxisomal bifunctional enzyme in transfected HepG2 cells reveals two regulatory motifs. FEBS Lett 1995; 360: 183-186.
3. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010; 10: 365-376.
4. Park EY, Cho IJ, Kim SG. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res 2004; 64: 3701-3713.
5. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: From genes to physiology. Rec Prog Hormon Res 2001; 56: 239-263.
6. Reddy JK, Rao S, Moody DE. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res 1976; 36: 1211-1217.
7. Ohmura T, Ledda-Columbano GM, Piga R, Columbano A, Glemba J, Katyal SL, Locker J, Shinozuka H. Hepatocyte proliferation induced by a single dose of a peroxisome proliferator. Am J Pathol 1996; 148: 815-824.
8. Reddy JK, Reddy MK, Usman MI, Lalwani ND, Rao MS. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug. Environ Health Perspect 1986; 65: 317-327.
9. Cattley RC, Kato M, Popp JA, Teets VJ, Voss KS. Initiator-specific promotion of hepatocarcinogenesis by WY-14, 643 and clofibrate. Carcinogenesis 1994; 15: 1763-1766.
10. Lai DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2004; 22: 37-55.
11. Lake BG, Rumsby PC, Price RJ, Cunninghame ME. Species differences in hepatic peroxisome proliferation, cell replication and transforming growth factor-beta1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res 2000; 448: 213-225.
12. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 1993; 31: 857-907.
13. Luci S, Giemsa B, Hause G, Kluge H, Eder K. Clofibrate treatment in pigs: Effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents. BMC Pharmacol 2007; 7: 6. DOI: 10.1186/1471-2210-7-6.
14. Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand? J Mol Med 2005; 83: 774-785.
15. Nishimura J, Dewa Y, Muguruma M, et al. Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol Sci 2007; 97: 44-54.
16. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 1997; 18: 2029-2033.
17. Canuto RA, Muzio G, Maggiora M, et al. Rapid and extensive lethal action of clofibrate on hepatoma cells in vitro. Cell Death Differ 1997; 4: 224-232.
18. Shabalina IG, Panaretakis T, Bergstrand A, DePierre JW. Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells. Carcinogenesis 1999; 20: 2237-2246.
19. Simbula G, Pibiri M, Sanna L, Cossu C, Molotzu F, Columbano A, Ledda-Columbano GM. The peroxisome proliferator BR931 kills FaO cells by p53-dependent apoptosis. Life Sci 2004; 75: 271-286.
20. Maggiora M, Bologna M, Ceru MP, et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer 2004; 112: 909-919.
21. Muzio G, Maggiora M, Oraldi M, Trombetta A, Canuto RA. PPARalpha and PP2A are involved in the proapoptotic effect of conjugated linoleic acid on human hepatoma cell line SK-HEP-1. Int J Cancer 2007; 121: 2395-2401.
22. Muzio G, Trombetta A, Maggiora M, et al. Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression. Free Radic Biol Med 2006; 40: 1929-1938.
23. Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA, Muzio G. Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact 2007; 165: 239-250.
24. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Nat Acad Sci USA 1998; 95: 8806-8811.
25. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-405.
26. Muzio G, Martinasso G, Trombetta A, Di Simone D, Canuto RA, Maggiora M. HMG-CoA reductase and PPARalpha are involved in clofibrate-induced apoptosis in human keratinocytes. Apoptosis 2006; 11: 265-275.
27. Tomiyama N, Yasuda N, Iwano C, Matzno S, Matsuyama K. Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clin Exp Pharmacol Physiol 2007; 34: 876-880.
28. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, Kim YK. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006; 215: 198-207.
29. Ryu JY, Whang J, Park H, et al. Di(2-ethylhexyl) phthalate induces apoptosis through peroxisome proliferators-activated receptor-gamma and ERK 1/2 activation in testis of Sprague-Dawley rats. J Toxicol Environ Health A 2007; 70: 1296-1303.
30. Avis I, Martínez A, Tauler J, et al. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005; 65: 4181-4190.
31. Barbiero G, Duranti F, Bonelli G, Amenta JS, Baccino FM. Intracellular ionic variations in the apoptotic death of L cells by inhibitors of cell cycle progression. Exp Cell Res 1995; 217: 410-418.
32. Oraldi M, Trombetta A, Biasi F, Canuto RA, Maggiora M, Muzio G. Decreased polyunsaturated fatty acid content contributes to increased survival in human colon cancer. J Oncol 2009; 2009: 867-915; DOI: 10.1155/2009/867915.
33. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
34. Shi Y. Assembly and structure of protein phosphatase 2A. Sci China C Life Sci 2009; 52: 135-146.
35. Clemencet M-C, Muzio G, Trombetta A, Peters JM, Gonzalez FJ, Canuto RA, Latruffe N. Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate. Cancer Lett 2005; 222: 217-226.
36. Peters JM, Hennuyers N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisomeproliferator-activated receptor alpha deficient mice. J Biol Chem 1997; 272: 27307-27312.
37. CherkaouiMalki M, Passilly P, Jannin B, Clemencet M-C, Latruffe N. Carcinogenic aspect of xenobiotic molecules belonging to the peroxisome proliferator family. Int J Mol Med 1999; 3: 163-168.
38. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998; 17: 339-346.